Skip to main content

Table 2 Summary of eight cases of IBD using VDZ in the presence of opportunistic infections

From: Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report

Reference

Age

Gender

Years

IBD

Opportunistic infections

Other comorbidities

Activity of IBD before VDZ

Treatment of IBD before VDZ

Treatment of opportunistic infections

Status of opportunistic infections at VDZ initiation

Follow-up after VDZ

Our case

56

M

2022

UC

Cryptococcal pneumonia

CMV infection

History of Sweet's syndrome

Moderate exacerbation

PSL, AZA, and GMA

Fluconazole

under treatment (Cryptococcal pneumonia)

Remission

11

57

F

2021

CD

Cryptococcal pneumonia

CMV infection

SLE

Existence of rectovaginal fistula

PSL, ADA, hydroxychloroquine, and transverse colostomy

Valganciclovir, amphotericin B and flucytosine

Cured by treatments

Remission, but the fistula persisted

12

74

M

2017

UC

Pneumonia with Staphylococcus haemolyticus

Hemophilia A, coronary artery disease, type 2 DM, and PSC

Remission

Mesalamine, IFX, and history of using 6-mercaptopurine

NA

NA

Remission

13

30

M

2019

CD

CMV pneumonia, pneumocystis pneumonia, and herpes simplex virus infection

HIV infection

Increased bowel movement frequency and elevated CRP

History of using ADA

NA

Cured by treatments

Remission

14

18

F

2019

UC

CMV infection

TPMT deficiency

NA

PSL

None

Positive for CMV immunostain on colon biopsy

Remission

15

21

M

2020

UC

CMV infection

NA

Flare

Steroid, IFX, and history of using GLM

GCV

Cured by treatments

Remission, but then flared and required proctocolectomy

16

33

M

2020

UC

CMV infection

PSC

Flare

IFX, ADA, and GLM

GCV and discontinuation of AZA

Occurred during VDZ administration

Response+

17

47

M

2021

CD

CMV infection

Liver cirrhosis (due to HCV and alcoholism)

Multiple rectal fistulas and presacral abscess

Antibacterial drug and transverse colostomy

GCV and valganciclovir

Under treatment

Remission

  1. ADA adalimumab, ART antiretroviral therapy, AZA azathioprine, CD Crohn’s disease, CMV cytomegalovirus, CRP C-reactive protein, DM diabetes mellitus, GCV ganciclovir, GMA granulocyte and monocyte adsorption apheresis, GLM golimumab, HCV hepatitis C virus, HIV human immunodeficiency virus, IBD inflammatory bowel disease, IFX infliximab, mPSL methylprednisolone, NA not available, PSC primary sclerosing cholangitis, PSL prednisolone, SLE systemic lupus erythematosus, TPMT thiopurine S-methyltransferase, UC ulcerative colitis, VDZ vedolizumab